Bellicum Pharmaceuticals [clinicaltrials_resource:ccab76db4cf6f4a95c56b7d7cb0fd350]
collaborator [clinicaltrials_vocabulary:collaborator]
MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer [clinicaltrials:NCT00868595]Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant [clinicaltrials:NCT01744223]Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer [clinicaltrials:NCT01823978]Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant [clinicaltrials:NCT02065869]Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases [clinicaltrials:NCT02231710]Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant [clinicaltrials:NCT02477878]Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies [clinicaltrials:NCT02487459]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer [clinicaltrials:NCT00868595]Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant [clinicaltrials:NCT01744223]Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer [clinicaltrials:NCT01823978]Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant [clinicaltrials:NCT02065869]Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases [clinicaltrials:NCT02231710]Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant [clinicaltrials:NCT02477878]Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies [clinicaltrials:NCT02487459]
source [clinicaltrials_vocabulary:source]
Bellicum Pharmaceuticals [clinicaltrials_resource:ccab76db4cf6f4a95c56b7d7cb0fd350]
Bio2RDF identifier
ccab76db4cf6f4a95c56b7d7cb0fd350
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:ccab76db4cf6f4a95c56b7d7cb0fd350
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:ccab76db4cf6f4a95c56b7d7cb0fd350
title
Bellicum Pharmaceuticals
@en
type
label
Bellicum Pharmaceuticals [clinicaltrials_resource:ccab76db4cf6f4a95c56b7d7cb0fd350]
@en